Chemo, radiation, and immunotherapy for older adults with esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests combining chemoradiation with the immunotherapy drug iparomlimab for adults aged 70 and older with advanced esophageal cancer. The goal is to see if adding immunotherapy after standard chemoradiation improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 70 years or older.
- You have a type of esophageal cancer called squamous cell carcinoma that has spread to nearby lymph nodes but not to distant organs (except possibly the collarbone lymph nodes).
- You are starting treatment for the first time and have not had chemotherapy, radiation, or other cancer treatments before.
- You are able to take care of yourself (ECOG performance status 0 or 1).
- You have tumor tissue available for testing (a recent biopsy or older sample within 6 months).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy and radiation for older adults (70+) with advanced esophageal cancer that hasn't been treated before. The goal is to see if this approach can help control the cancer while keeping quality of life.
This trial compares two treatment sequences for people with locally advanced esophageal cancer that cannot be removed with surgery. One group gets immunotherapy first, then chemoradiation; the other gets chemoradiation first, then immunotherapy. The goal is to find which order works better.
This trial tests giving chemotherapy plus immunotherapy first, followed by standard chemoradiation, for people with advanced esophageal cancer that cannot be surgically removed. It aims to see if this approach improves outcomes.
This trial compares two approaches for people with esophageal cancer that has shrunk or disappeared after initial chemotherapy combined with immunotherapy. It looks at whether adding targeted radiation (DCRT) or surgery is better. The goal is to find the most effective next step for eligible patients.
This trial tests whether giving chemotherapy and immunotherapy before surgery is safe and effective for older adults (70+) with a certain type of esophageal cancer. It aims to find a treatment approach that works well for patients who haven't had cancer treatment before.
This trial tests the safety and effectiveness of combining two immunotherapy drugs (iparomlimab and tuvonralimab) with a chemotherapy drug (nab-paclitaxel) before surgery for people with a certain type of esophageal cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.